Q2 FY26: Consolidated revenue up 26%, PAT jumps 34% YoY
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.0 pts more than Nifty Microcap 250 and 7.1 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Advanced Enzyme Technologies posted strong Q2 FY26 results. Consolidated revenue rose 26% YoY to Rs 1,845 million with PAT up 34% at Rs 447 million. H1 FY26 revenue grew 23% to Rs 3,704 million and PAT rose 25% to Rs 852 million. EBITDA margins held steady at about 35%. Operating cash flow improved to Rs 647 million from Rs 430 million last year. Auditors gave an unqualified opinion. Company flagged US tariffs as a watchpoint but said the impact was immaterial so far.
Strong topline and bottomline growth with stable margins and improving cash flows. US tariffs remain a key risk to monitor.